Steve Horrigan

Dr. Horrigan serves as an advisor to NeuImmune and oversees its preclinical development program. He is an accomplished molecular geneticist who is known for his contributions to the development of innovative approaches for using genomic profiles and biomarkers to enhance drug discovery and development. Dr. Horrigan currently serves as the chief scientific officer for Noble Life Sciences, a leading pre-clinical research organization. At Noble, he leads a team to determine pharmacology and pharmacokinetics of therapeutic molecules and their evaluation in animal models, including IND enabling studies.

Prior to joining Noble, Dr. Horrigan was the vice president of research at Avalon Pharmaceuticals, a wholly-owned subsidiary of Clinical Data, Inc., and played a key role in development of the company's unique genomic biomarker-driven R&D platform. He has strong expertise in the cellular control mechanisms of cancer, and use of biomarkers for the discovery and development of therapeutics in which he holds multiple publications and patents in this area. Prior to joining Avalon, Dr. Horrigan was associate professor in the Department of Pediatrics and Lombardi Cancer Center at Georgetown University Medical Center. As Georgetown, he led a research group focused on cancer genomics and the application of biomarkers in cancer diagnostics. He also held positions at the University of Chicago Medical School and the University of Illinois.